| EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Aromatase
inhibitors in early breast cancer
ATAC (‘ARIMIDEX’, TAMOXIFEN, ALONE OR IN COMBINATION)
COMPLETED TREATMENT ANALYSIS: ANASTROZOLE DEMONSTRATES SUPERIOR
EFFICACY AND TOLERABILITY COMPARED WITH TAMOXIFEN.
BENEFITS OF SWITCHING POSTMENOPAUSAL
WOMEN WITH HORMONE-SENSITIVE EARLY BREAST CANCER TO ANASTROZOLE
AFTER 2 YEARS ADJUVANT TAMOXIFEN: COMBINED RESULTS FROM 3,123
WOMEN ENROLLED IN THE ABCSG TRIAL 8 AND THE ARNO 95 TRIAL.
THE INTERGROUP EXEMESTANE STUDY: A RANDOMIZED
TRIAL IN POSTMENOPAUSAL PATIENTS WITH EARLY BREAST CANCER
WHO REMAIN DISEASE-FREE AFTER TWO TO THREE YEARS OF TAMOXIFEN-UPDATED
SURVIVAL ANALYSIS.
Breast
cancer chemotherapy
FIVE YEARS ANALYSIS OF THE PACS 01 TRIAL: 6 CYCLES OF FEC100
VS 3 CYCLES OF FEC100 FOLLOWED BY 3 CYCLES OF DOCETAXEL (D)
FOR THE ADJUVANT TREATMENT OF NODE POSITIVE BREAST CANCER.
A RANDOMIZED, MULTICENTER PHASE III
TRIAL COMPARING REGIMENS OF DOXORUBICIN + CYCLOPHOSPHAMIDE
FOLLOWED BY PACLITAXEL OR DOXORUBICIN + PACLITAXEL FOLLOWED
BY WEEKLY PACLITAXEL AS ADJUVANT THERAPY FOR PATIENTS WITH
HIGH RISK BREAST CANCER.
CONCURRENT (CAFT) VERSUS SEQUENTIAL
(CAF-T) CHEMOHORMONAL THERAPY (CYCLOPHOSPHAMIDE, DOXORUBICIN,
5-FLUOROURACIL, TAMOXIFEN) VERSUS T ALONE FOR POSTMENOPAUSAL,
NODE-POSITIVE, ESTROGEN (ER) AND/OR PROGESTERONE (PGR) RECEPTOR-POSITIVE
BREAST CANCER: MATURE OUTCOMES AND NEW BIOLOGIC CORRELATES
ON PHASE III INTERGROUP TRIAL 0100 (SWOG-8814).
| 
